Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Diagnosis and Treatment of Cancer Cachexia

Pfizer Inc.

Cancer cachexia is a wasting disorder defined by an unintentional weight loss of > 5% or >2% if the patient has a BMI < 20 kg/m2 or sarcopenia. It is an under-diagnosed disorder. Prevalence of cachexia can vary between cancer types, but rates of cachexia are known to be high in pancreatic, gastric, esophageal and lung cancers. It effects not just body weight but also overall quality of life including how patients feel and function. Additionally, clinical evidence has demonstrated cachexia can diminish a patient’s ability to tolerate therapy which may have a negative impact on overall survival.

This RFP is seeking proposals for independent education initiatives that will improve the ability of healthcare professionals to:

• Recognize the signs and symptoms of cachexia.

• Use diagnostic tools to assess, measure and correctly document cachexia in patient records.

• Utilize current strategies to improve appetite, lean body mass, or physical function in patients with cachexia.

• Become familiar with the mechanism of GDF-15 and its role as a target in cachexia treatment.

• Consider patients for a cachexia clinical trial, understanding the status of new therapeutic options currently in development.

Grant Application due date: May 13, 2025

Specialties

Curriculum Development

Medical - Clinical Science

Medical

Medical - Translational

Eligibility Requirements

Geographic Scope/Location of Project: United States, United Kingdom, France, Spain, Germany, Italy, and Japan are the priority countries although proposals with global reach are also encouraged.

• Applicant organizations to this RFP must be based in the United States, one of the 5-European countries above, or Japan. • The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; hospitals and healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. • Only organizations are eligible to receive grants, not individuals or physician-owned medical practices or individual-physician-owned organizations. • If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project. • For projects offering continuing education credit in the United States, the requesting organization must be accredited.

Sponsor Details

Sponsor Institute/Organizations: Pfizer Inc.

Sponsor Type:

Address: 66 Hudson Boulevard East New York, NY 10001-2192 USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity